DNA (and RNA) read, write and editing includes the primary methods in which nucleic acids are analyzed (sequencing), created (synthesis) and modified (gene editing). It is becoming increasingly important in the life sciences industry to be expert in all aspects of nucleic acids in order to exploit significant opportunities within this industry. The end users for these technologies include any industry that works with biological systems, and even some that don’t (e.g., DNA data storage).
The DNA read, write and edit industry is at the beginning stages of its growth story; penetration of the key markets is still at an early stage. For example, the cumulative number of human genomes sequenced reached REDACTED as of January 2019 (less than REDACTED of the global human population); we estimate that population-scale projects alone will increase that figure to more than REDACTED genomes sequenced during the next five years. The percentage of non-human species sequenced as of January 2019 was less than REDACTED of all species. These data indicate that there is significant future upside for sequencing across research, metagenomics, agriculture, synthetic biology and clinical applications,
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/4445593-global-dna-read-write-and-edit-market
The situation is similar for DNA writing and editing technologies, with clinical therapeutic applications in particular providing an enormous total available future market that is yet to be significantly penetrated. Major successes in this industry include the adoption of next-generation sequencing (NGS) for noninvasive prenatal testing; enabling the roles of synthetic DNA oligonucleotides and genes in the rise of the synthetic biology industry; and rapid adoption of CRISPR gene editing by research institutions and biopharma industries.
There is increasing interplay among the three DNA technology platforms, giving rise to innovative corporate strategies. For example, Arbor Biotechnologies employs sequencing, gene synthesis and artificial intelligence to perform high-throughput discovery of biomolecules, including new CRISPR proteins.
The scope of the report includes DNA read, write and edit technologies, applications, industries, initiatives, patents and companies. The markets for read, write and edit products and services are given for 2017, 2018, 2019 (estimated) and 2024 (forecast).
This report reviews the main read, write and edit technologies and explains why genetic variation is important in clinical testing and disease. It then discusses significant large-scale research initiatives that impact read, write and edit applications. Of particular interest is a discussion of population-scale sequencing projects throughout the world, and their likely impact. The main market driving forces for read, write and edit products and services are listed and discussed.
The report quantifies each of the main market segments. The read (sequencing) market is quantified by delivered format, including sequencing workflow products (sample preparation kits and reagents, sequencing instruments and consumables, and informatics) and sequencing services (clinical diagnostics and sequencing services to applied market customers).
The sequencing workflow products market is quantified by type, that is, DNA isolation and extraction; target enrichment; library preparation; and informatics/ecosystems. The sequencing instruments and consumables market is given by platform (Sanger, NGS and 3GS).
The sequencing services market is analyzed by end user application (applied, clinical, and R&D). Within sequencing services, the applied market is analyzed by end-user application (agriculture, biopharma, consumer, microbiology, population-scale genomics, synthetic biology and other).
Also within sequencing services, the clinical market is analyzed and quantified by disease category (cardiovascular, clinical microbiology and infectious diseases, Mendelian disorders, metabolic/immune disorders, neurology, oncology, reproductive health and transplant medicine).
The DNA write (synthesis) market is quantified by product type (oligonucleotides, synthetic biology parts, genes and RNA therapeutics). The oligonucleotide market is analyzed by application (gene editing, sequencing, PCR, FISH, microarray, gene synthesis and other). The gene market is quantified by gene type (standardized, value-added). Finally, the RNA therapeutics market is quantified by platform (RNA interference, antisense oligos, micro RNA modulation and mRNA) and by disease category (cancer, hematology, musculoskeletal, neurology and rare diseases).
The DNA edit (gene editing) market is quantified by application (agriculture, biopharma, diagnostics and therapeutics); editing platform (CRISPR, meganuclease, TALEN, ZFN). The gene editing agriculture market is analyzed by product type (crop/seeds, livestock). The gene editing biotechnology market is analyzed by product type (kits and reagents, cell line engineering, animal models and services). The gene editing therapeutics market is analyzed by disease category (eye and rare diseases).
Specific geographic markets discussed include North America, Europe, Asia-Pacific, and the rest of the world (ROW).
Industry sectors analyzed include next-generation sequencing; long read sequencing; DNA synthesis; RNA therapies; and gene editing.
More than 320 companies in the read, write and edit industry are profiled in this report.
WGR Research also provides a summary of more than 180 of the main industry acquisitions and strategic alliances that took place from January 2018 through June 2019, including key alliance trends.
– 28 data tables and 77 additional tables
– An overview of the global market for DNA read, write and edit technologies, applications, and industries
– Analyses of global market trends, with market data from 2017, 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
– Discussion on sequencing technologies, market applications, industry structure, and important clinical sequencing initiatives
– Information pertaining to several significant large-scale research initiatives that are contributing to sequencing services, write synthesis and gene editing technologies’ market development
– A look at the innovations in pharmaceutical and biotechnology companies and research & development programs in stem cell-based therapies and gene therapies
– Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
– Company profiles of over 320 major global players within the industry, including 3Billion Inc., 23Andme Inc., Bayer AG, Becton, Dickinson and Co. (BD), Bio-Rad Laboratories, Pacific Biosciences, Qiagen NV, Roche Holding AG and Thermo Fisher Scientific Inc.
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349